SCHEMBL379602

SCHEMBL379602

Fc1ccc(-c2csc3ccnc(NCc4ccccc4)c23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE11A Q9HCR9 1/20 0.47
ESR1 P03372 3/20 0.47
TP53 P04637 2/20 0.45
CCNC P24863 1/20 0.45
CDK8 P49336 1/20 0.45
FGFR1 P11362 1/20 0.45
MAPK1 P28482 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TNF P01375 1/20 0.43
NOD1 Q9Y239 1/20 0.43
MAPK14 Q16539 1/20 0.43
UTS2R Q9UKP6 1/20 0.43
KDR P35968 3/20 0.42
AURKA O14965 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4946829 0.99 PDE11A (0.49) PDE11AESR1TP53CCNCCDK8
SCHEMBL379865 0.91 ESR1 (0.55) PDE11AESR1CCNCCDK8MAPK1
SCHEMBL379757 0.88 CCNC (0.47) ESR1TP53CCNCCDK8MAPK1
SCHEMBL380531 0.84 UTS2R (0.47) MAPK1L3MBTL1KDM4EALDH1A1ALOX15
SCHEMBL379790 0.83 KDM4E (0.52) ESR1MAPK1L3MBTL1KDM4EALDH1A1
SCHEMBL379868 0.80 TUBB4A (0.45) KDM4EALDH1A1GAAKDRLMNA
SCHEMBL379896 0.79 CLK4 (0.59) TP53MAPK1KDM4EALDH1A1GAA
SCHEMBL379904 0.78 UTS2R (0.49) ESR1MAPK1KDM4EALDH1A1TSHR
SCHEMBL379387 0.78 TNF (0.69) MAPK1L3MBTL1ALDH1A1TNFNOD1
SCHEMBL379643 0.78 CYP1A2 (0.58) TP53CCNCCDK8FGFR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 PDE11A 4642/4885ESR1 4761/4885TP53 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.